One pharmacologic intervention with potential to address diabetes mellitus, obesity and associated cardiometabolic conditions in patients with obstructive sleep apnea is glucagon-like peptide-1 receptor agonists (GLP-1RAs). Here, GLP1R is linked to diabetes mellitus.